Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuMAIN: HU6 in Obese HFpEF
NCT05284617Phase 2Completed
- Sponsor
- Rivus Pharmaceuticals, Inc.
- Start
- Oct 2022
- Primary completion
- May 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HU6 in heart failure with preserved ejection fraction (HFpEF), sponsored by Rivus Pharmaceuticals, Inc.. Started Oct 2022; status: completed.
02
Drugs
HU6
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05284617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284617.